The latest update is out from Climb Bio ( (CLYM) ).
On March 27, 2025, Climb Bio, Inc. experienced changes in its board of directors with the resignation of Simon Tate and the decision of Adam Rosenberg not to seek re-election. Both directors clarified that their decisions were not due to disagreements with the company’s operations or policies. On March 28, 2025, the board expanded from seven to eight members, electing Alexander (Bo) Cumbo and Kimberlee (Kim) Drapkin as new directors. Cumbo and Drapkin will serve in various committee roles and receive compensation in line with the company’s non-employee director compensation policy. These changes are part of the company’s ongoing governance adjustments and may influence its strategic direction.
More about Climb Bio
YTD Price Performance: -41.06%
Average Trading Volume: 363,012
Technical Sentiment Signal: Buy
Current Market Cap: $86.37M
See more data about CLYM stock on TipRanks’ Stock Analysis page.